Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
GlobeNewswire
· Friedreich’s ataxia is a rare, genetic, life-shortening, debilitating, and neurodegenerative disorder
· Treatment with..